Provider reasons for discontinuing long-term opioid therapy following aberrant urine drug tests differ based on the type of substance identified

Jessica J. Wyse, Benjamin J. Morasco, Steven K. Dobscha, Michael I. Demidenko, Thomas H.A. Meath, Travis I. Lovejoy

Research output: Contribution to journal › Article › peer-review

3 Scopus citations

Fingerprint

Dive into the research topics of 'Provider reasons for discontinuing long-term opioid therapy following aberrant urine drug tests differ based on the type of substance identified'. Together they form a unique fingerprint.

Medicine & Life Sciences